Better Therapeutics, Inc. is a clinical-stage digital therapeutics company developing prescription therapies to address the underlying causes of cardiometabolic diseases. The company’s flagship platform delivers cognitive behavioral therapy via a mobile application designed to help patients modify lifestyle behaviors that contribute to conditions such as type 2 diabetes and cardiovascular disease. By combining personalized coaching, real-time data analytics and tailored educational content, Better Therapeutics aims to improve long-term health outcomes beyond what traditional pharmaceutical interventions alone can achieve.
The company’s lead program, BT-001, has been studied in randomized clinical trials to evaluate its safety, efficacy and impact on glycemic control and cardiovascular risk factors. Better Therapeutics has secured Breakthrough Device designation from the U.S. Food and Drug Administration, reflecting its innovative approach to digital prescription therapeutics. In addition to developing proprietary software, the company collaborates with academic research centers and healthcare providers to generate clinical evidence and optimize patient engagement.
Headquartered in Redwood City, California, Better Therapeutics primarily serves the U.S. market, working with health plans, provider organizations and employer groups to integrate its digital treatments into existing care pathways. The company is also exploring opportunities for regulatory approval and market expansion in Europe and select Asia-Pacific regions. Strategic partnerships with payers and medical device companies are intended to support reimbursement and broader adoption of digital therapy solutions.
Founded in 2015 by seasoned digital health entrepreneurs, Better Therapeutics went public on the NASDAQ under the ticker BTTX. The management team is led by Chief Executive Officer Erika Davis, whose background spans clinical research and digital health innovation. The board of directors comprises experts in biotechnology, software development and regulatory affairs, positioning the company to navigate the evolving landscape of prescription digital therapeutics.
AI Generated. May Contain Errors.
